Profiel
Michelle Gates is currently Chief People Officer at CAMP4 Therapeutics Corp.
since 2021.
Formerly, Ms. Gates was Vice President-Human Resources at Akamai Technologies, Inc. from 2005 to 2021, Human Resources Manager at Teradyne, Inc. from 2004 to 2005, and Human Resources Director at British Telecommunications Ltd. from 2001 to 2004.
Ms. Gates completed undergraduate education at Providence College.
Actieve functies van Michelle Gates
| Bedrijven | Functie | Begin |
|---|---|---|
| CAMP4 THERAPEUTICS CORPORATION | Human Resources Officer | 01-06-2021 |
Eerdere bekende functies van Michelle Gates
| Bedrijven | Functie | Einde |
|---|---|---|
| AKAMAI TECHNOLOGIES, INC. | Human Resources Officer | 01-06-2021 |
| TERADYNE, INC. | Human Resources Officer | 01-01-2005 |
British Telecommunications Plc
British Telecommunications Plc Major TelecommunicationsCommunications Provides telecommunication services | Human Resources Officer | 01-01-2004 |
Opleiding van Michelle Gates
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Teradyne, Inc.
Teradyne, Inc. Electronic Production EquipmentElectronic Technology Designs, manufactures, markets and services electronic test systems | Electronic Technology |
Akamai Technologies, Inc.
Akamai Technologies, Inc. Data Processing ServicesTechnology Services Provides cloud computing, security and content delivery services | Technology Services |
British Telecommunications Plc
British Telecommunications Plc Major TelecommunicationsCommunications Provides telecommunication services | Communications |
Providence College
Providence College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
















